76Bio Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Out of Business

  • Employees
  • 9

Employees

  • Latest Deal Type
  • Out of Business

76Bio General Information

Description

Developer of a biotechnology platform designed to degrade or break down unneeded proteins. The company offers targeted protein degraders, enabling healthcare organizations to treat patients suffering from life-threatening diseases with the next generation of targeted protein degradation therapies.

Contact Information

Website
www.76bio.com
Formerly Known As
TRC 2001
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 40 Guest Street
  • Boston, MA 01235
  • United States
+1 (212)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 40 Guest Street
  • Boston, MA 01235
  • United States
+1 (212)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

76Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 29-Jan-2025 Completed Out of Business
3. Early Stage VC 14-Feb-2023 Completed Generating Revenue
2. Seed Round 07-Jan-2022 $10M $10M Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view 76Bio’s complete valuation and funding history, request access »

76Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed
To view 76Bio’s complete cap table history, request access »

76Bio Patents

76Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024081913-A1 Dual-specific bifunctional fusion proteins for ubiquitin-mediated degradation Inactive 14-Oct-2022
WO-2023215839-A1 Bifunctional fusion proteins for ubiquitin-mediated degradation Inactive 06-May-2022

76Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

76Bio Investments (1)

76Bio’s most recent deal was a Seed Round with Axelyf for . The deal was made on 29-Aug-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Axelyf 29-Aug-2025 Seed Round Drug Discovery
To view 76Bio’s complete investments history, request access »

76Bio FAQs

  • When was 76Bio founded?

    76Bio was founded in 2020.

  • Where is 76Bio headquartered?

    76Bio is headquartered in Boston, MA.

  • What is the size of 76Bio?

    76Bio has 9 total employees.

  • What industry is 76Bio in?

    76Bio’s primary industry is Drug Discovery.

  • Is 76Bio a private or public company?

    76Bio is a Private company.

  • What is 76Bio’s current revenue?

    The current revenue for 76Bio is .

  • How much funding has 76Bio raised over time?

    76Bio has raised $22.2M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process